152 related articles for article (PubMed ID: 37198599)
21. Licensing of Orphan Medicinal Products-Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021.
Naumann-Winter F; Wolter F; Hermes U; Malikova E; Lilienthal N; Meier T; Kalland ME; Magrelli A
Front Pharmacol; 2022; 13():920336. PubMed ID: 36034814
[No Abstract] [Full Text] [Related]
22. The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs.
Scavone C; di Mauro G; Mascolo A; Berrino L; Rossi F; Capuano A
Front Pharmacol; 2019; 10():111. PubMed ID: 30814951
[TBL] [Abstract][Full Text] [Related]
23. Access to novel cancer medicines in four countries in Central and Eastern Europe in relation to clinical benefit.
Hofmarcher T; Szilagyiova P; Gustafsson A; Dolezal T; Rutkowski P; Baxter C; Karamousouli E
ESMO Open; 2023 Aug; 8(4):101593. PubMed ID: 37413761
[TBL] [Abstract][Full Text] [Related]
24. Price comparison of high-cost originator medicines in European countries.
Vogler S; Zimmermann N; Babar ZU
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
[TBL] [Abstract][Full Text] [Related]
25. Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines.
Zarkavelis G; Amylidi AL; Verbaanderd C; Cherny NI; Metaxas Y; de Vries EGE; Zygoura P; Amaral T; Jordan K; Strijbos M; Dafni U; Latino N; Galotti M; Lordick F; Giuliani R; Pignatti F; Pentheroudakis G
ESMO Open; 2023 Feb; 8(1):100604. PubMed ID: 36870739
[TBL] [Abstract][Full Text] [Related]
26. The impact of expanded access programs for systemic anticancer therapy in an Irish cancer centre.
Cronin TK; Ronayne C; O'Donovan N; McGuinness E; Cooke K; Dennehy M; Dennehy C; Power DG; Cahill MR; Collins DC; Connolly RM; Bambury RM; Mykytiv V; Higgins MJ; Noonan SA; O'Reilly S
Ir J Med Sci; 2024 May; ():. PubMed ID: 38806877
[TBL] [Abstract][Full Text] [Related]
27. Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries.
Post HC; Schutte T; van Oijen MGH; van Laarhoven HWM; Hollak CEM
ESMO Open; 2023 Apr; 8(2):101208. PubMed ID: 37030113
[TBL] [Abstract][Full Text] [Related]
28. Current national initiatives about drug policies and cost control in Europe: the Italy example.
Rocchi F; Addis A; Martini N;
J Ambul Care Manage; 2004; 27(2):127-31. PubMed ID: 15069990
[TBL] [Abstract][Full Text] [Related]
29. [Duration of the Reimbursement Process in Spain for Innovative Drugs Approved by the European Medicines Agency during the Period 2008-2013].
Pinyol C; Valmaseda A; Gómez-Ulloa D; Solozabal M; Restovic G
Rev Esp Salud Publica; 2015 Apr; 89(2):189-200. PubMed ID: 26121628
[TBL] [Abstract][Full Text] [Related]
30. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
31. Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.
Vilhelmsson A; Davis C; Mulinari S
PLoS Med; 2016 Jan; 13(1):e1001945. PubMed ID: 26812151
[TBL] [Abstract][Full Text] [Related]
32. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
[TBL] [Abstract][Full Text] [Related]
33. [Analysis of the evolution in the access to orphan medicines in Spain].
Mestre-Ferrándiz J; Iniesta M; Trapero-Bertran M; Espín J; Brosa M
Gac Sanit; 2020; 34(2):141-149. PubMed ID: 31014554
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK.
Lafuma A; Brézin A; Lopatriello S; Hieke K; Hutchinson J; Mimaud V; Berdeaux G
Pharmacoeconomics; 2006; 24(2):193-205. PubMed ID: 16460138
[TBL] [Abstract][Full Text] [Related]
35. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.
Kandolf Sekulovic L; Guo J; Agarwala S; Hauschild A; McArthur G; Cinat G; Wainstein A; Caglevic C; Lorigan P; Gogas H; Alvarez M; Duncombe R; Lebbe C; Peris K; Rutkowski P; Stratigos A; Forsea AM; De La Cruz Merino L; Kukushkina M; Dummer R; Hoeller C; Gorry C; Bastholt L; Herceg D; Neyns B; Vieira R; Arenberger P; Bylaite-Bucinskiene M; Babovic N; Banjin M; Putnik K; Todorovic V; Kirov K; Ocvirk J; Zhukavets A; Ymeri A; Stojkovski I; Garbe C
Eur J Cancer; 2018 Nov; 104():201-209. PubMed ID: 30388700
[TBL] [Abstract][Full Text] [Related]
36. Time to Entry for New Cancer Medicines: From European Union-Wide Marketing Authorization to Patient Access in Belgium, Estonia, Scotland, and Sweden.
Ferrario A
Value Health; 2018 Jul; 21(7):809-821. PubMed ID: 30005753
[TBL] [Abstract][Full Text] [Related]
37. [Access to medicines in France].
Bouvenot G; Bouvenot J
Bull Acad Natl Med; 2009 Mar; 193(3):649-59; discussion 659-62. PubMed ID: 19883016
[TBL] [Abstract][Full Text] [Related]
38. Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations.
Polak TB; Cucchi DGJ; van Rosmalen J; Uyl-de Groot CA; Darrow JJ
Front Pharmacol; 2022; 13():913567. PubMed ID: 35677436
[TBL] [Abstract][Full Text] [Related]
39. Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology.
Löblová O; Csanádi M; Ozierański P; Kaló Z; King L; McKee M
Health Policy; 2019 Jul; 123(7):630-634. PubMed ID: 31130319
[TBL] [Abstract][Full Text] [Related]
40. The current state of understanding of oncology expanded access programs in Malaysia.
Yong FL; Tan WC
Med J Malaysia; 2024 Mar; 79(2):191-195. PubMed ID: 38553925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
